Pharmacokinetics of Dexmedetomidine in Morbid Obesity
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine hydrochloride ,a relatively new drug in Chinais ,is a highly selective,
potent a2-adrenoceptor agonist with significant analgesic, sedative and anxiolytic effects.
The morbid obesity in Chinese population is rapidly increasing. But the pharmacokinetics of
the drug in these people is still unknown.This research was designed to study the
pharmacokinetics of dexmedetomidine in Chinese morbidly obese population.
Phase:
Phase 4
Details
Lead Sponsor:
Guangzhou General Hospital of Guangzhou Military Command